[1]张江宇,王颀,朱彩霞.血管内皮标记物在乳腺癌演变中得表达及意义[J].中华乳腺病杂志(电子版),2007,1(2):25.
 ZHANG Jiang-yu,WANG Qi,ZHU Cai-xia.Expression of CD105,FⅧ,CD31 and CD34 in evolution of breast carcinoma[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):25.
点击复制

血管内皮标记物在乳腺癌演变中得表达及意义()

中华乳腺病杂志(电子版)[ISSN:1674-0807/CN:11-9146/R]

卷:
第1卷
期数:
2007年2期
页码:
25
栏目:
实验研究
出版日期:
2007-04-01

文章信息/Info

Title:
Expression of CD105,FⅧ,CD31 and CD34 in evolution of breast carcinoma
作者:
张江宇;王颀;朱彩霞
广东省妇幼保健院暨广州医学院附属广东省妇儿医院病理科(张江宇、张佳立、陈文静),乳腺中心(王颀、朱彩霞、李文萍、 陈中扬)
Author(s):
ZHANG Jiang-yu;WANG Qi;ZHU Cai-xia
关键词:
乳腺癌CD105微血管密度FⅧCD31CD3
摘要:
目的 探讨乳腺癌演变中新生血管表达状况,旨在选择乳腺癌发生发展中新生血管的特异性标记物。方法 采用免疫组化(SP)法,分别以CD105、FⅧ、CD31、CD34为标记,对100例乳腺不同病变组织,包括乳腺导管上皮不典型增生(ADH)、导管内癌(DCIS)、微浸润导管癌(MDC)各20例,40例非特殊类型浸润型导管癌(IDC,NOS),计算微血管密度(MVD)。结果 ADH、DCIS、MDC和IDC(NOS)中,CD105标记的MVD分别为8.25±5.78、10.05±4.23、25.35±7.62和37.33±5.86,FⅧ标记的MVD分别为10.60±8.99、16.60±3.47、16.90±5.62和17.90±5.62,CD31标记的MVD分别为16.80±3.90、19.40±4.58、20.74±6.67和22.74±6.67,CD34标记的MVD分别为14.40±12.82、25.20±5.39、26.32±4.89和40.32±4.89,仅CD105标记的MVD各组间两两比较差异有统计学意义(P <0.05)。结论 CD105标记MVD用来评估乳腺癌发生发展中的新生血管表达,可能更具价值,这将为今后抗血管生成的治疗提供理论依据。

相似文献/References:

[1]蒋宏传.乳腺癌根治术后乳房再造方法的选择[J].中华乳腺病杂志(电子版),2007,1(1):1.
 JIANG Hong-chuan.Selection of breast reconstlh_paperctive method after radical resection in breast cancer[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):1.
[2]王永胜.乳腺癌前哨淋巴结活检研究进展[J].中华乳腺病杂志(电子版),2007,1(1):7.
 YANG Ming-tian,LIAN Zheng-qiang.Advancement of endocrine therapy in breast cancer[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):7.
[3]杨名添,连臻强.乳腺癌内分泌治疗的进展[J].中华乳腺病杂志(电子版),2007,1(1):14.
 WANG Yong-sheng.Advancement of sentinel lymph node in breast cancer[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):14.
[4]刘鹏熙,钟少文,陈前军.乳腺癌保乳术后背阔肌微肌瓣转移乳房整形[J].中华乳腺病杂志(电子版),2007,1(1):25.
 LIAN Peng-xi,ZHONG Shao-wen,CHEN Qian-jun.The use of a lastissimus doris miniflap for immediate correction of the deformity resulting from breast conservation surgery[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):25.
[5]王毅本,盛桦,曾小兵.乳腺癌术后引流液细胞学检查得临床价值[J].中华乳腺病杂志(电子版),2007,1(1):29.
 WANG Yi-ben,SHENG Hua,ZENG Xiao-bing.Examination of exfoliative cytology of draining liquid in patients with breast tumor[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):29.
[6]王水,刘晓安,赵佳.联合法观察前哨淋巴通道的临床研究[J].中华乳腺病杂志(电子版),2007,1(1):55.
 WANG Shui,LIU Xiao-an,ZHAO Jia.The study on sentinel lymphatic channels by using methylene blue and technetium 99m sulfur colloid in breast cancer patients[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):55.
[7]曾晓华,刘长安,邓建川.RNAi 抑制hTERT基因治疗乳腺癌的实验研究[J].中华乳腺病杂志(电子版),2007,1(1):61.
 ZENG Xiao-hua,LIU Chang-an,DENG Jian-chuan.Experimental research of targeting hTERT gene inhibited in breast cancer therapy by RNA interference[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):61.
[8]陈治,耿翠芝.植物雌激素与乳腺癌关系得研究进展[J].中华乳腺病杂志(电子版),2007,1(1):67.
 CHEN Zhi,GEGN Cui-zhi.Advancement of the relationship between phytoestrogen and breast cancer[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):67.
[9]唐鹏,姜军.类固醇受体辅活化因子家族与乳腺癌[J].中华乳腺病杂志(电子版),2007,1(1):74.
 TANG Peng,JIANG Jun.steroid receptor coactivator family and breast cancer[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):74.
[10]徐海滨,胡组健,胡望华.乳腺癌骨转移综合治疗初探[J].中华乳腺病杂志(电子版),2007,1(1):87.
 XU Hai-bin,HU Zu-jian,HU Wang-hua.Preliminary exploration of combined therapy in bone metastasis of breast cancer[J].Chinese Journal of Breast Disease (Electronic Version),2007,1(2):87.

更新日期/Last Update: 2007-01-20